natgillin/translations-raw huggingface dataset:
Process for removing H2S from a H2S contaminated energy production gas stream containing methane, using an aqueous biofilter system (10) comprising a biofilter (6) having biofilter support material constituting a biofilter bed supporting a humidified biofilm having microorganisms that are capable of oxidizing H2S, wherein the process comprises the steps of 
Postupak za uklanjanje H>S 1z struje plina za proizvodnju energije koja sadržava metan, onečišćene s H,S, korištenjem vodenog biofiltra (10), koji se sastoji od biofiltra (6) s materijalom nosača biofiltra koji čimi nosivi sloj biofiltra na koji je postavljen ovlaženi biofilm s mikroorganizmima koji mogu oksidirati H2S, pri čemu postupak obuhvaća korake:
A method according to claim 1, wherein the sample is a maternal sample. 
Postupak prema zahtjevu 1, naznačen time da je uzorak majčin uzorak.
The compound of claim 1, wherein the antidepressant and anti-anxiety agents are selected from the group consisting of benzodiazepines, enzodiazepines, barbiturates, glutelhimide, chloral hydrate, meprobamate, sertraline, escitalopram, fluoxetine, venlafaxine, citalopram, paroxetine, trazodone, amitriptyline, and bupropion. 
Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens antidepresivni i anksiolitički agens izabran iz grupe koja se sastoji od benzodiazepina, enzodiazepina, barbiturata, glutetimida, kloral hidrata, meprobamata, sertralina, escitaloprama, fluoksetina, venlafaksina, citaloprama, paroksetina, trazodona, amitriptilina, i bupropiona.
After this, the perforated area of the attachment portion is placed against the data portion. 
Nakon toga se perforirani prostor predjela za povezivanje stavi do predjela za podatke.
a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the light chain variable domain sequence of L5; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji je najmanje 80% identičan slijedu SEQ ID NO:362;
subjecting the mixture to mild homogenization at about 10 bar, 
lagano homogeniziranje smjese pod tlakom od oko 10 bara,
In another embodiment, in formula (VII), X42 is CR44, and R43 and R44 are, independently, selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu su R43 1 Ru nezavisno izabrani iz skupine koju čine -H, metil, etil, propil, izopropil i ciklopropil.
One R4 is Hydrogen, and the other R4 is selected from the group consisting of Hydrogen, halogen, C1-C3alkyl, cyclopropyl, CHF2, CH2F and CF3; 
Ro s (1) naznačen time što je R* odabran iz skupine koja sadrži vodik, halogen, C;-Csalkil, ciklopropil, CHF2, CH>F i CFs.
The composition for use according to claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is provided at least one of sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed acute myeloid leukemia (AML) subject, to maintain remission in a subject, or in a relapsed or acute myeloid leukemia (AML) subject. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli osigurana barem jednom slijedno ili istodobno s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije kod subjekta ili subjektu s relapsiranom ili akutnom mijeloičnom leukemijom (AML).
• a signal is generated by a detector of said flammable gas release, by an operator, by an approaching flame or by the explosion itself, 
pomoću detektora bude izazvan signal oslobađanja zapaljivog plina ili operatera ili preko približavjućeg požara ili preko same eksplozije ili bilo koje njihove kombinacije,
condensing a compound represented by the formula (IX): wherein X and m are as defined above, and R1c is alkyl which may be substituted by A, cycloalkyl which may be substituted by A, alkenyl which may be substituted by A, alkynyl which may be substituted by A, aryl or a heterocyclic group, and the compound of the above formula (V); or 
(5) kondenziranje spoja prikazanog formulom (IX): (X) gdje su X i m kao što je definirano gore, R'" je alkil koji može biti supstituiran sa A, cikloalkil koji može biti supstituiran sa A, alkenil koji može biti supstituiran sa A, alkinil koji može biti supstituiran sa A, aril ili heterociklička skupina i spoj prema gornjoj formuli (V); ili
ivb) adding an amine group to the 6 position of the pyridyl moiety to produce compound 6a, wherein the amination reaction is carried out in the presence of a sulfonyl compound, and wherein R is H, C1-6 aliphatic, aryl, aralkyl, heteroaryl, cycloalkyl, or heterocycloalkyl and R1, o, and p are as defined for compounds 2a and 3a above. 
ivb) dodavanje amino grupe na položaj 6 piridil grupe da se proizvede spoj 6a, [image] pri čemu se reakcija aminacije izvodi u prisustvu sulfonil spoja, pri čemu, R je H, C1-6 alifat, aril, aralkil, heteroaril, cikloalkil ili heterocikloalkil; i, o i p su kako je prethodno definirano za spojeve 2a i 3a.
For all positions discussed in the present invention, numbering is according to the EU index as in Kabat (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda, entirely incorporated by reference). 
Antitijelo koje sadrži dvije modifikacije u odnosu na divlji tip humane Fc regije, naznačeno time da su navedene modifikacije 428L 1 4348, pri čemu navedeno antitijelo ima kod sisavca duži poluživot u odnosu na antitijelo bez navedenih modifikacija, i pri čemu je numeriranje u skladu s EU indeksom u Kabat i sur., za uporabu kao lijek.
The pharmaceutical composition of claim 1 and 8, wherein the pharmaceutical composition is a solid dosage form takes the form of a bilayer tablet. 
Farmaceutski pripravak prema zahtjevima 1 i 8, naznačen time što je navedeni farmaceutski pripravak u čvrstom obliku koji je formuliran kao dvoslojna tableta.
The process of paragraph 1, wherein said second solvent is selected from the group consisting of ethers, ketones, esters, amides, sulfoxides, aliphatic hydrocarbons, aromatic hydrocarbons, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine eteri, ketoni, esteri, amidi, sulfoksidi, alifatski ugljikovodici, aromatski ugljikovodici, te smjese 2 ili više njih.
FIG. 6 is a schematic partial section of the discharge device with the metered dose valve according to the first embodiment of the present invention in the second position; 
prikazuje shematski djelomičan presjek naprave za pražnjenje s ventilom za odmjeravanje doze prema prvoj izvedbi predloženog izuma u drugom položaju; slika 7 = prikazuje shematski presjek sredstva za zabravljivanje naprave za pražnjenje u međupoložaju; slika 8
Solubility in Fasted State Simulated Intestinal Fluid (FaSSIF) 
Topljivost u stimuliranoj crijevnoj tekućini tijekom izgladnjivanja (FaSSIF)
to provide a compound of formula (IV): 
* kako bi se dobio spoj formule (TV):
The polypeptide of any one of the preceding claims, wherein the polypeptide does not compete for binding to myostatin with ActRIIB and/or the polypeptide competes for binding to myostatin with ALK4 and/or ALK5. 
Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se polipeptid ne natječe za vezanje na miostatin s ActRIIB i/ili se polipeptid natječe za vezanje na miostatin s ALK4 i/ili ALKS5.
C10-C26 monoalcohols, such as lauryl alcohol, isostearyl alcohol, oleyl alcohol, 2-hexyldecyl alcohol, isocetyl alcohol and octyldodecanol, and mixtures thereof; 
C10-C26 monoalkohola, kao što je lauril alkohol, izostearil alkohol, oleil alkohol, 2-heksildecil alkohol, izocetil alkohol i oktildodekanol, i njihovih smjesa;
ii) treating the mixture with a base to obtain a mixture comprising compound (V), and iii) optionally, isolating a compound (V) from the mixture. 
1i) obradu smjese lužinom radi dobivanja smjese koja sadrži spoj (V), 1 ili) izborno, izolaciju spoja (V) iz smjese.
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, pri čemu formulacija matrice s produljenim otpuštanjem nakon što je skladištena pri 25 *€ i 60 % relativne vlažnosti zraka barem 1 mjesec daje stupanj otapanja, kad je mjerena u USP uređaju (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez prisustva enzima (SGF) pri 37 *C, naznačen time da je postotna količina aktivnog agensa oslobođena pri 1, 4 ili 12 sati otapanja koja odstupa ne više od oko 15 % točaka od odgovarajuće in-vitro stupnja otapanja referentne formulacije prije skladištenja.
An ophthalmic aqueous solution for treating ocular hypertension and glaucoma, comprising PGF2a analogue as an active ingredient, wherein said ophthalmic aqueous solution contains nonionic surfactant, stabilizing agent and substantially no preservatives in a container consisting essentially of polyethylene; and the polyethylene is low density polyethylene (LDPE). 
Oftalmološka vodena otopina koja sadrži 0.0015% tež./zap. tafluprost kao aktivni sastojak, 0.075% tež./zap. polisorbat 80, 0.05% tež./zap. dinatrijev edetat, 2.25% tež./zap. glicerol, 0.2% tež./zap. natrijev dihidrogen fosfat dihidrat, vodu i sredstva za podešavanje pH kao pomoćne tvari, u spremniku koji se u bitnome sastoji od polietilena.
The method of claim 1 or 2, wherein water content has been added to the waste in order to achieve an appropriate non-water content, and/or wherein an appropriate non-water content is achieved by adding to the MSW a constant mass ratio of water between 0.5 and 2.5 kg water per kg MSW. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se otpadu dodaje sadržaj vode kako bi se postiglo prikladan sadržaj nevodenih tvari, i/ili što se prikladan sadržaj nevodenih tvari postiže dodavanjem u MSW konstantnog masenog omjera vode između 0,5 1 2,5 kg vode po kg MSW.
comprises a mature type I elastase protein having an activity of 20 to 100 U/mg of protein as quantified using a colorimetric N-succinyl-Ala-Ala-Ala-pNitroanilide (SLAP) hydrolysis assay, wherein the upper limit of trypsin in said pharmaceutical composition is less than 25 ng of trypsin per 1 mg of mature type I elastase protein, and optionally wherein: 
(b) obuhvaća zreli tip protein elastaze koji ima aktivnost od 20 do 100 U/mg proteina kao kvantificiranog koristeći kolorimetrijski N-sukcinil-Ala-Ala-Ala-pNitroanilid (SLAP) hidrolizacijski test, pri čemu je gornja granica tripsina u spomenutom farmaceutskom sastavu manja od 25 ng tripsina po 1 mg zrelog tipa protein elastaze, i pri čemu opcionalno:
The capsule holder 111 is accommodated in its support 115 which has a lateral wall 124 and a bore 127 for the passage of extracted coffee beverage. 
Držač 111 čašice je prihvaćen u svojem nosaču 115, koji nosač ima bočnu stijenku 124 i otvor 127 za prolaz napitka od kave koja se istače.
A pharmaceutical or diagnostic composition containing at least one IL-6 antibody or fragment according to any one of claims 1 - 3 and a pharmaceutically acceptable carrier. 
Farmaceutski ili dijagnostički sastav koji sadrži najmanje jedno anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3 1 farmaceutski prihvatljivi nosač.
connecting regions (518) having a local basis weight that is lower than the local basis weight of the fiber-enriched regions (512), the connecting regions (518) interconnecting the fiber-enriched regions. 
spojnim područjima (18) koja tvore mrežu koja međusobno spaja nadsvođena područja (12), spojna područja (18) imaju lokalnu osnovnu masu koja je manja od lokalne osnovne mase nadsvođenih područja (12); i
Glucono-δ-lacton enhances the perception of the initial sweet taste of Neohesperidine DC. 
Glukono-Å -lakton pojačava početnu percepciju slatkog okusa neohesperidina DC.
A compound selected in the following list: as well as the corresponding mercapto derivatives, or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers. 
a OI M. O kao i odgovarajući merkapto derivati, ili njihovi farmaceutski prihvatljiv soli, hidrati, ili hidratirane soli, ili polimorfne kristalne strukture tih spojeva ili njihovi optički izomeri, racemati, dijastereomeri ili enantiomeri.
System for treating water at low cost, according to claim 1, wherein the receiving means is covered with a material comprising membranes, geo-membranes, geotextile membranes, plastic liners, concrete, or coated concrete, or a combination thereof. 
Postupak za obradu vode uz nizak trošak, prema zahtjevu 1, naznačen time što se informacije koje primaju koordinacijska sredstva dobivaju vizualnim pregledom, algoritmima koji se temelje na iskustvu, elektronskim detektorima ili njihovim kombinacijama.
An exact separation of the arrangement 1, with simultaneous exposure of the corresponding nozzle 5, or of the opposite end of the groove structure 4, or of the inlet of a corresponding filter structure, is effected by sawing with a high-speed (often higher than 20,000 rpm) diamond circular saw, for example, exactly along these lines 6 or more precisely between two such lines 6. 
Točno odvajanje naprave 1, s istovremenim izlaganjem odgovarajuće mlaznice 5, ili suprotnog kraja brazdaste strukture 4, ili jastučica odgovarajuće filtarske strukture, vrši se piljenjem velikom brzinom (često većom od 20.000 okr./min) s dijamantnom kružnom pilom, na primjer, točno uzduž tih linija 6 ili točnije između dviju takovih linija 6.
Cup (1) as claimed in one of the preceding claims, characterized in that the wall section (4) is arranged inclined with respect to the peripheral direction (U) at an angle. 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da je dio stijenke (4) postavljen koso u odnosu na obodni smjer (U) pod kutom a.
The results demonstrate that although both control mice and mice treated with Isomer B both exhibited some progression in the symptoms typical of Huntington's disease during the first three days following administration, the mice treated with Isomer B exhibited significantly less deterioration than the control mice during the period of 17 to 24 days after administration. 
Rezultati pokazuju da premda oba, kontrolni miš i onaj tretiran Izomerom B, pokazuju neku progresiju simptoma tipičnih za Huntington-ovu bolest za vrijeme prva tri dana nakon primjene, miševi tretirani Izomerom B pokazuju znatno slabije pogoršanje stanja u odnosu prema kontrolnim miševima za vrijeme razdoblja od 17 do 24 dana nakon primjene.
it specifically binds to the extracellular domain of CD127 and 
specifično se vezuje za izvastaničnu domenu CD127 1
In contrast, the immediate mixing of the cream with sugar replacer did result in a stable whipped cream. 
Nasuprot tome, trenutnim miješanjem slatkog vrhnja sa zamjenom za šećer dobiveno je stabilno tučeno slatko vrhnje.
Preferably, the biologically degradable composite material is characterised in that the inorganic component (a) is present in an amount of 2-20% by weight, based on the composite material; the inorganic component (b) is present in an amount of 60-78% by weight, based on the composite material, and the organic component (c) is present in an amount of 10-20% by weight, based on the composite material, with the proviso that the total amount of the components contained in the composite material is not more than 100% by weight. 
Biološki razgradivi kompozitni materijal u skladu s patentnim zahtjevom 1, naznačen time što je anorganska komponenta (a) prisutna u količini od 2-20% po masi, na temelju kompozitnog materijala; anorganska komponenta (b) prisutna je u količini od 60-78% po masi, temeljena na kompozitnom materijalu, a organska komponenta (c) prisutna je u količini od 10-20% po masi, na temelju kompozitnog materijala, uz uvjet da količina komponenti sadržanih u kompozitnom materijalu nije veća od 100% po masi.
The capsule according to claim 1, wherein the filtering material of the third wall is a sheet of filtering paper. 
Kapsula prema bilo kojem od prethodnih zahtjeva, naznačena time, da je zbijeni sastojak za piće dopremljen u obliku tablete.
The method of anyone of the preceding claims, wherein the non- biodegradable solids separated comprise at least about 20% of the dry weight of the MSW, and/or wherein the non-biodegradable solids separated comprise at least about 20% by dry weight of recyclable materials. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što odvojene bionerazgradljive krutine čine u najmanju ruku otprilike 20 % suhe težine MSW, i/ili što odvojene bionerazgradljive krutine čine u najmanju ruku otprilike 20 % suhe težine obnovljivih materijala.
for a compound of Formula I wherein R2 is hetAr2 or a phenyl ring which is optionally substituted with NHSO2(1-4C alkyl), reacting a corresponding compound of Formula II with a corresponding compound having the formula HOC(═O)R2 in the presence of a coupling reagent and a base; or 
(c) za spoj Formule I, gdje je R* hetAr? ili fenilni prsten izborno supstituiran s NHSO,(1-4C alkilom), reakciji odgovarajućeg spoja Formule H s odgovarajućim spojem formule HOC(=0)R", u prisutnosti kondenzacijskog sredstva i baze; ili
The gypsum wall board of claim 1, wherein the substituted starch is of an acid-thinned starch and the at least one ether group is of a hydroxypropyl group. 
Zidna gips ploča prema zahtjevu 1, naznačena time, da je supstituirani škrob od škroba razrjeđenog kiselinom 1 barem jedna eterska skupina je iz hidroksipropilne skupine.
is hydrogen or C1-4 aliphatic; and Ring D is an optionally substituted mono- or bicyclic aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring. 
je vodik ili C1-4 alifatična grupa; i prsten D je izborno supstituirani mono- ili biciklični aril, heteroaril, heterociklil ili cikloalifatični prsten.
are 9 to 30, 9 to 20 or 13 to 17 amino acids in length; and/or 
su 9 do 30, 9 do 20 ili 13 do 17 aminokiselina u duljini, i/ili
To 10 mL solutions containing 5 g of freeze dried decolourised caramel, prepared according to example 1, 0, 0.5, 1.0, 2.0 and 4 grams of the cation exchange material was added. 
U 10 mL-otopine koje sadržavaju 5 g liofilizirane obezbojene karamele, pripremljene prema primjeru 1, dodano je 0, 0,5, 1,0, 2,0 1 4 grama kation izmjenjivačkog materijala.
This advantageous effect of this substance has not so far been mentioned in the literature and could not be aforeseen. 
Ovaj blagotvoran učinak ove tvari dosad nije bio spomenut u literature i ne treba ga zaobići.
The mixture was heated to 50° C., an additional 300 uL chlorotrimethylsilane was added, and the reaction mixture maintained at elevated temperature. 
Smjesa je zagrijana do 50 *C, dodano je još 300 uL klorotrimetil silana, 1 reakcjska smjesa održavana kod rastuće temperature.
a mouthpiece enabling the patient to inhale the medicament in dry powder form from the opened blister; 
- nastavak za usta (14) koji omogućava pacijentu inhaliranje lijeka u suhom praškastom obliku iz otvorenog blistera koji je u uporabi;
Orchidectomy (orx) or sham operation was performed under isoflurane anaesthesia. 
Orhidektomija (orx) ili lažna operacija provedena je pod izofluranskom anestezijom.
The footing according to claim 1, wherein said uprights comprise tubular profiled elements or elements made of bent sheet metal. 
Postolje u skladu s patentnim zahtjevom 1, naznačeno time, da navedeni uspravni držači (3) sadržavaju cjevaste profilirane elemente i / ili elemente izrađene od savijenog lima.
The receiver of paragraph 14, wherein the length of the data slice ID information is 8 bits. 
Prijamnik iz patentnog zahtjeva 14, pri čemu duljina ID informacije podatkovnog reza iznosi 8 bitova.
Machine (1) according to the claim 7, characterized by the fact that said first edge (17) and said second edge (24) are defined by a profile having a L-shaped transversal section. 
Uređaj (1) sukladno zahtjevu 7, naznačen time što prvi rub (17) i drugi rub (24) su definirani transverzalnim dijelom profila oblika L.
In a preferred embodiment, the effective amount is about 10 to about 15 milligrams of aminopyridine. 
Sastav prema zahtjevu 1, naznačen time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 5 do 10 miligrama aminopiridina.
covering the reinforcement package, inclusive of the installed supply, substantially gas- or air-tightly, for instance by plastic foil; 
- < pokrivanje tijela za ojačanje, zajedno s priključenim dodovom, uglavnom nepropusno za plin ili zrak, na primjer s plastičnom folijom;
The present invention is not limited by specific container forms or designs, as long as the container is acceptable for its intended use and standards therefore. 
Predstavljeni izum nije ograničen određenim oblicima ili dizajnima pakiranja, sve dok je pakiranje prihvatljivo za njegovu namjeravanu uporabu i standarde.
A counter as described in embodiment 1 further comprising a coupling mechanism for releasably coupling said first ring member to said second ring member, to allow said first and second ring members to rotate cooperatively when coupled and to allow independent rotating of said first ring member when not coupled. 
Brojač kao što je navedeno u zahtjevu 1 dalje sadržeći mehanizam sparivanja (700) za odvojivo sparivanje navedenog prvog prstenastog elementa (201) s navedenim drugim prstenastim elementom (202, 1510), kako bi se omogućilo navedenim prvom i drugom prstenastom elementu da kooperativno rotiraju kad spareni te kako bi se omogućilo samostalno rotiranje navedenog prvog prstenastog elementa kad nije sparen.
"ammonium" refers to a positively charged group -N+RR'R" where R, R' and R" are independently "C1-C6 alkyl", "C1-C6 alkyl aryl", "C1-C6 alkyl heteroaryl," "cycloalkyl," or "heterocycloalkyl," and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring; 
"amonij" se odnosi na pozitivno nabijenu grupu -N"RR'R" u kojoj su R, R' i R" nezavisno "C,-Cg alkil", "C-C alkil aril", "C;-C4 alkil heteroaril", "cikloalkil", ili "heterocikloalkil", i gdje R i R', zajedno s atomom dušika za koji su vezani, mogu opcionalno formirati 3-8-člani heterocikloalkilni prsten;
The present invention relates to the field of pharmaceutical technology and describes an aqueous pharmaceutical preparation comprising a slightly soluble PDE 4 inhibitor as active ingredient. 
Prikazani izum se odnosi na područje farmaceutske tehnologije 1 opisuje vodeni farmaceutski pripravak koji sadrži slabo topiv PDE 4 inhibitor kao aktivni sastojak.